A Phase 1 Study of LY3039478 in Japanese Patients with Advanced Solid Tumors I6F-JE-JJCC

Eli Lilly Japan K.K.0 个研究点开始时间: 待定最近更新: 2018年12月17日

试验速览

暂无简介。

•Histological or cytological evidence of a diagnosis of solid tumor that is advanced and/or metastatic.
•In the judgment of the investigator, participants must be appropriate candidates for experimental therapy after available standard therapies have failed or for whom standard therapy is not appropriate.
•Performance status of less than or equal to 1 on the Eastern Cooperative Oncology Group (ECOG) scale.
•Adequate organ function, including hematologic, hepatic, and renal.
•Estimated life expectancy of more than or equal to 12 weeks.

•Received previous therapy for cancer within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agents, respectively.
•Have serious preexisting medical conditions.
•Have current or recent (within 3 months of study drug administration) gastrointestinal disease with chronic or intermittent diarrhea.
•Have an active bacterial, fungal, and/or known viral infection.
•Have known acute or chronic leukemia or current hematologic malignancies that may affect the interpretation of results.

发起方